Summit Therapeutics (SMMT) Share-based Compensation (2019 - 2026)

Summit Therapeutics has reported Share-based Compensation for 8 years, with the latest figure at $72.8 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 556.01% year-over-year to $72.8 million; the trailing twelve-month figure through Mar 2026 stood at $794.1 million (up 1410.59% YoY), and the FY2025 full-year result was $732.4 million, up 1336.65% from the prior year.
• Share-based Compensation for Q1 2026 stood at $72.8 million, down from $111.8 million in the prior quarter.
• The five-year high for Share-based Compensation was $478.8 million in Q2 2025, with the low at $705000.0 in Q3 2023.
• Historically, Share-based Compensation has averaged $51.9 million across 5 years, with a median of $9.5 million in 2024.
• Annual changes were most pronounced in 2023 — Share-based Compensation sank 74.8% — and 2025, when it surged 4218.04%.
• Summit Therapeutics' Share-based Compensation stood at $2.7 million in 2022, then jumped by 229.31% to $8.8 million in 2023, then advanced by 25.84% to $11.0 million in 2024, then surged by 914.79% to $111.8 million in 2025, then tumbled by 34.88% to $72.8 million in 2026.
• The last three Share-based Compensation figures came in at $72.8 million (Q1 2026), $111.8 million (Q4 2025), and $130.8 million (Q3 2025), per Business Quant data.